The cyclooxygenase-1 C50T polymorphism is not associated with aspirin responsiveness status in stable coronary artery disease in tunisian patients

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 7-8, 2011, Pages 513-516

  Chakroun, Tahar ^a   Addad, Faouzi ^b   Yacoub, Saloua ^a   Abderrezak, Fatma ^b   Gerotziafas, Gregoris T ^c   Abdelkafi, Sadia ^a   Hassine, Mohssen ^b   Gamra, Habib ^b   Hatmi, Mohamed ^c   Elalamy, Ismail ^c  

^a FARHAT HACHED HOSPITAL   (Tunisia)

^b FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ADRENALIN; COLLAGEN; CYCLOOXYGENASE 1; GENOMIC DNA;

ARTICLE; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; GENE FREQUENCY; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTE FUNCTION; TREATMENT RESPONSE; TUNISIA; URINARY EXCRETION; URINE LEVEL;

ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; CYCLOOXYGENASE 1; DRUG RESISTANCE; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; THROMBOXANE B2; TUNISIA;

EID: 79960441325     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2010.0225     Document Type: Article

References (19)

1. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324:71-86.
2. Chakroun T, Addad F, Abderazek F, et al. (2007) Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res 121:413-418.
3. Clappers N, Van Oijen MGH, Sundaresan S, et al. (2008) The C50T polymorphism of cyclooxygenase-1 gene and risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost 100:70-75. (Pubitemid 351948747)
4. Feher G, Feher A, Pusch G, et al. (2009) The genetics of anti-platelet drug resistance. Clin Genet 75:1-18.
5. Gonzalez-Conejero R, Rivera J, Corral J, et al. (2005) Biological assesment of aspirin efficacy on healthy individuals: heterog-enous response or aspirin failure? Stroke 36:276-280. (Pubitemid 40170808)
6. Goodman T, Ferro A, Sharma P (2008) Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 66:222-232.
7. Goodman T, Sharma P, Ferro A (2007) The genetics of aspirin resistance. Int J Clin Pract 61:826-834. (Pubitemid 46587879)
8. Gum PA, Kottke-Marchant K, Poggio ED, et al. (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230-235. (Pubitemid 32721947)
9. Halushka MK, Walker LP, Halushka PV (2003) Genetic variation in cyclooxygenase 1: effect on response to aspirin. Clin Pharmacol Ther 73:122-130. (Pubitemid 36158493)
10. Hillarp A, Palmqvist B, Lethagen S, et al. (2003) Mutation within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res 112:275-283. (Pubitemid 38373757)
11. Krasopoulos G, Brister SJ, Beattie WS, et al. (2008) Aspirin «resistance» and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336:195-198. (Pubitemid 351212675)
12. Kunicki TJ, Williams SA, Nugent DJ, et al. (2009) Lack of association between aspirin responsivness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost 101:123-133.
13. Lee CR, Bottone FG Jr., Krahn JM, et al. (2007) Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS-1). Pharmacogenet Genomics 17:145-160.
14. Lee CR, North KE, Bray MS, et al. (2008) Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 83:52-60.
15. Lepäntalo A, Mikkelson J, resendiz JC, et al. (2006) Polymorphism of COX-1 and GPVI associated with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Hae-most 95:253-259.
16. Maree AO, Curtin RJ, Chubb A, et al. (2005) Cyclooxygenase 1 haplotype modulates platelet response to aspirin. J Thromb Haemost 3:2340-2245.
17. Patrono C, Bachmann F, Baigent C, et al. (2004) Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 25:166-181. (Pubitemid 38112156)
18. Pettinella C, Romano M, Stuppia L, et al. (2009) Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. Thromb Haemost 101:687-690.
19. Ulrich CM, Bigler J, Sibert J, et al. (2002) Cyclooygenase 1 (COX1) polymorphism in African-American and Caucasian populations. Hum Mutat 20:409-410.